128 related articles for article (PubMed ID: 26749044)
1. ERBB-2 overexpression as a risk factor for malignant phaeochromocytomas and paraganglinomas.
Wang W; Zhong X; Ye L; Qi Y; Su T; Wei Q; Xie J; Jiang L; Jiang Y; Zhou W; Cui B; Ning G
Clin Endocrinol (Oxf); 2016 Jun; 84(6):822-9. PubMed ID: 26749044
[TBL] [Abstract][Full Text] [Related]
2. Establishment and evaluation of a novel biomarker-based nomogram for malignant phaeochromocytomas and paragangliomas.
Zhong X; Ye L; Su T; Xie J; Zhou W; Jiang Y; Jiang L; Ning G; Wang W
Clin Endocrinol (Oxf); 2017 Aug; 87(2):127-135. PubMed ID: 28429830
[TBL] [Abstract][Full Text] [Related]
3. Value of Immunohistochemical Expression of Apelin, Succinate Dehydrogenase B, Chromogranin B, Human Epidermal Growth Factor Receptor-2, Contactin 4, and Succinyl-CoA Synthetase Subunit Beta in Differentiating Metastatic From Non-Metastatic Pheochromocytoma and Paraganglioma.
Wang Y; Chen D; Pang Y; Xu X; Guan X; Liu L
Front Endocrinol (Lausanne); 2022; 13():882906. PubMed ID: 35574028
[TBL] [Abstract][Full Text] [Related]
4. MicroRNA-210 May Be a Preoperative Biomarker of Malignant Pheochromocytomas and Paragangliomas.
Ruff SM; Ayabe RI; Malekzadeh P; Good ML; Wach MM; Gonzales MK; Tirosh A; Nilubol N; Pacak K; Kebebew E; Patel D
J Surg Res; 2019 Nov; 243():1-7. PubMed ID: 31146085
[TBL] [Abstract][Full Text] [Related]
5. Expression of Contactin 4 Is Associated With Malignant Behavior in Pheochromocytomas and Paragangliomas.
Evenepoel L; van Nederveen FH; Oudijk L; Papathomas TG; Restuccia DF; Belt EJT; de Herder WW; Feelders RA; Franssen GJH; Hamoir M; Maiter D; Ghayee HK; Shay JW; Perren A; Timmers HJLM; van Eeden S; Vroonen L; Aydin S; Robledo M; Vikkula M; de Krijger RR; Dinjens WNM; Persu A; Korpershoek E
J Clin Endocrinol Metab; 2018 Jan; 103(1):46-55. PubMed ID: 28938490
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma.
Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F
Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135
[TBL] [Abstract][Full Text] [Related]
7. Disentangling of Malignancy from Benign Pheochromocytomas/Paragangliomas.
Kim KY; Kim JH; Hong AR; Seong MW; Lee KE; Kim SJ; Kim SW; Shin CS; Kim SY
PLoS One; 2016; 11(12):e0168413. PubMed ID: 27992508
[TBL] [Abstract][Full Text] [Related]
8. Germline mutations and genotype-phenotype correlations in patients with apparently sporadic pheochromocytoma/paraganglioma in Korea.
Kim JH; Seong MW; Lee KE; Choi HJ; Ku EJ; Bae JH; Park SS; Choi SH; Kim SW; Shin C; Kim SY
Clin Genet; 2014 Nov; 86(5):482-6. PubMed ID: 24134185
[TBL] [Abstract][Full Text] [Related]
9. Epidemiology and Prognosis of Pheochromocytoma/Paraganglioma in Korea: A Nationwide Study Based on the National Health Insurance Service.
Kim JH; Moon H; Noh J; Lee J; Kim SG
Endocrinol Metab (Seoul); 2020 Mar; 35(1):157-164. PubMed ID: 32207276
[TBL] [Abstract][Full Text] [Related]
10. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of ERBB-2 was more frequently detected in malignant than benign pheochromocytomas by multiplex ligation-dependent probe amplification and immunohistochemistry.
Yuan W; Wang W; Cui B; Su T; Ge Y; Jiang L; Zhou W; Ning G
Endocr Relat Cancer; 2008 Mar; 15(1):343-50. PubMed ID: 18310300
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas.
de Krijger RR; van der Harst E; van der Ham F; Stijnen T; Dinjens WN; Koper JW; Bruining HA; Lamberts SW; Bosman FT
J Pathol; 1999 May; 188(1):51-5. PubMed ID: 10398140
[TBL] [Abstract][Full Text] [Related]
13. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma.
Zhang J; Li M; Pang Y; Wang C; Wu J; Cheng Z; Li X; Lu Z; Liu Y; Guo J; Chen X; He Y; Guan X; Xu X; Wang Y; Liu J; Guo W; Hou Y; Liu L; Jiang J; Gao X
J Clin Endocrinol Metab; 2022 Apr; 107(5):e1835-e1842. PubMed ID: 35106577
[TBL] [Abstract][Full Text] [Related]
14. New Insights into the Nuclear Imaging Phenotypes of Cluster 1 Pheochromocytoma and Paraganglioma.
Taïeb D; Pacak K
Trends Endocrinol Metab; 2017 Nov; 28(11):807-817. PubMed ID: 28867159
[TBL] [Abstract][Full Text] [Related]
15. Proliferative index in phaeochromocytomas: does it predict the occurrence of metastases?
van der Harst E; Bruining HA; Jaap Bonjer H; van der Ham F; Dinjens WN; Lamberts SW; de Herder WW; Koper JW; Stijnen T; Proye C; Lecomte-Houcke M; Bosman FT; de Krijger RR
J Pathol; 2000 Jun; 191(2):175-80. PubMed ID: 10861578
[TBL] [Abstract][Full Text] [Related]
16. Clinical differences between small and large pheochromocytomas and paragangliomas.
Zhao L; Li Z; Meng X; Fan H; Zhang Z; Zhang Z; Liu Y; Zhou X; Zhu H
Front Endocrinol (Lausanne); 2023; 14():1087506. PubMed ID: 36967797
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Intraoperative Hemodynamic Instability in Postoperatively Diagnosed Pheochromocytoma and Sympathetic Paraganglioma Patients.
Kim JH; Lee HC; Kim SJ; Lee KE; Jung KC
Front Endocrinol (Lausanne); 2022; 13():816833. PubMed ID: 35282440
[TBL] [Abstract][Full Text] [Related]
18. New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.
Crona J; Taïeb D; Pacak K
Endocr Rev; 2017 Dec; 38(6):489-515. PubMed ID: 28938417
[TBL] [Abstract][Full Text] [Related]
19. Recommendations for somatic and germline genetic testing of single pheochromocytoma and paraganglioma based on findings from a series of 329 patients.
Currás-Freixes M; Inglada-Pérez L; Mancikova V; Montero-Conde C; Letón R; Comino-Méndez I; Apellániz-Ruiz M; Sánchez-Barroso L; Aguirre Sánchez-Covisa M; Alcázar V; Aller J; Álvarez-Escolá C; Andía-Melero VM; Azriel-Mira S; Calatayud-Gutiérrez M; Díaz JÁ; Díez-Hernández A; Lamas-Oliveira C; Marazuela M; Matias-Guiu X; Meoro-Avilés A; Patiño-García A; Pedrinaci S; Riesco-Eizaguirre G; Sábado-Álvarez C; Sáez-Villaverde R; Sainz de Los Terreros A; Sanz Guadarrama Ó; Sastre-Marcos J; Scolá-Yurrita B; Segura-Huerta Á; Serrano-Corredor Mde L; Villar-Vicente MR; Rodríguez-Antona C; Korpershoek E; Cascón A; Robledo M
J Med Genet; 2015 Oct; 52(10):647-56. PubMed ID: 26269449
[TBL] [Abstract][Full Text] [Related]
20. Malignant Pheochromocytoma and Paraganglioma: 272 Patients Over 55 Years.
Hamidi O; Young WF; Iñiguez-Ariza NM; Kittah NE; Gruber L; Bancos C; Tamhane S; Bancos I
J Clin Endocrinol Metab; 2017 Sep; 102(9):3296-3305. PubMed ID: 28605453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
